Phosphorus is important not only for maintaining healthy bone metabolism but also for many other biological functions such as cell membrane integrity and cellular energy systems. In patients with end-stage renal disease, decreased renal excretion of phosphorus results in hyperphosphatemia, which causes secondary hyperparathyroidism and/or an increase in the serum calcium x phosphorus product. A high serum calcium x phosphorus product accelerates vascular calcification, 1 which is reported to be independently associated with mortality in patients on hemodialysis. 2,3 Hyperphosphatemia also is an independent risk factor for mortality in these patients. 2-4 For example, the relative mortality risk at a serum phosphate concentration greater than 6.5 mg/dL is more than twice (2.02; CI 1.10 to 3.73) that of a normal serum phosphate concentration (3.0-5.0 mg/dL), after adjusting for several factors. 5 A serum phosphate concentration greater than 5.0 mg/dL is independently associated with an increased risk of death in hemodialysis patients. 4
MINORI SATOH, AKIKO KOIZUMI, SATOSHI IZUMI, YASUHIRO KUGOH, ERIKOKIRIYAMA, EMIKO OGUMA, TAKU FURUKUBO, CHIHARU MATSUNAGA, TOMOYUKI YAMAKAWA, DAISUKE KADOWAKI, AND SUMIO HIRATA Background: Patient adherence to a phosphate binder treatment regimen is crucial in the management of hyperphosphatemia. Nonadherence may be due to a lack of patient knowledge of the nature and treatment of the illness.Objective: To investigate the effectiveness of pharmacist-provided education regarding phosphate binders and hyperphosphatemia on serum phosphate concentration and calcium x phosphorous product in hemodialysis patients.
Methods:A total of 398 hemodialysis patients who were prescribed phosphate binders participated in a pharmacist-run, education-based intervention session regarding phosphate binders and hyperphosphatemia. Each session was individualized on the basis of patient knowledge, assessed via a questionnaire. Particular attention was given to correcting patient misconceptions. Patients with elevated serum phosphate received additional education. Mean serum concentrations of phosphate and calcium, averaged from 4 measurements obtained at both baseline and postintervention, were compared to evaluate the efficacy of the intervention.Results: Postintervention, patients with the highest baseline serum phosphate concentrations (≥7.0 mg/dL) showed a significant decrease in mean ± SD serum concentrations of phosphate and calcium-phosphate product (7.4 ± 0.4 mg/dL and 72.6 ± 6.4 mg 2 /dL 2 to 6.5 ± 0.8 mg/dL and 63.1 ± 8.4 mg 2 /dL 2 , respectively; p < 0.001). Likewise, patients with serum phosphate concentrations ranging from 6.0-6.9 mg/dL showed a significant decrease in both parameters after educational intervention (p < 0.05 and p < 0.005, respectively).Conclusions: An education session regarding phosphate binders and hyperphosphatemia, provided by pharmacists for hemodialysis patients, appeared effective in reducing serum phosphate concentrations and calcium x phosphorus product, thus contri...